Get the Stockscreener App
71.91
2.77%
2.21
Moderna Inc stock is traded at $71.91, with a volume of 3.56M.
It is up +2.77% in the last 24 hours and up +51.79% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$69.70
Open:
$69.835
24h Volume:
3.56M
Relative Volume:
0.51
Market Cap:
$28.41B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-8.8274
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+17.43%
1M Performance:
+51.79%
6M Performance:
+135.55%
1Y Performance:
+159.62%
1-Day Range:
$69.83
$73.28
1-Week Range:
$57.91
$73.28
52-Week Range:
$22.28
$73.28
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
71.59 | 26.69B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
497.10 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
628.60 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.89 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.16 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.83 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Big Pharma Has a Case of Merger Mania - The Motley Fool
ETFs Investing in Moderna, Inc. Stocks - TradingView
Moderna Is Applying MRNA Technology in Vaccines, but Also Cancer and Rare Disease Therapies - Morningstar
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines - TradingView
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
MRNA Stock Spikes as Moderna Shares mRNA Pipeline Update - Barchart.com
Stock Of The Day: Will The Moderna Rally Continue? - Benzinga
Moderna (MRNA) Stock Soars 13% on Groundbreaking CAR-T Program Announcement - Blockonomi
Moderna (NASDAQ:MRNA) surge puts stock above most analyst targets ahead of FDA review - TechStock²
Patton Fund Management Inc. Has $4.49 Million Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna Stock Jumps 12% as Pipeline Reset Puts Aug. 5 FDA Catalyst in Focus - FXLeaders
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA - Stocktwits
Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week - TechStock²
Moderna (MRNA) Stock Soars 13% on In Vivo CAR-T Breakthrough and Flu Vaccine Progress - Blockonomi
SG Americas Securities LLC Sells 27,930 Shares of Moderna, Inc. $MRNA - MarketBeat
The mRESVIA from Moderna Inc.RSV protection moves beyond Covid - Ad-hoc-news.de
S&P 500 ends lower; chips tumble and Moderna rallies - Yahoo Finance
MRNA Stock Surges As Flu Win And Pipeline Shift Grab Attention - timothysykes.com
Wall Street ends mixed; chips tumble and Moderna rallies - marketscreener.com
Trending: Netflix stock bounces back, Moderna surges post–investor day, ON Semi plummets - Yahoo Finance
Moderna stock soars as cancer pipeline and CAR-T push ignite optimism - Invezz
MRNA Maintained by Piper Sandler -- Price Target Raised to $77.0 - GuruFocus
Moderna Shares Up on New Research Efforts for Autoimmune Disorder - WSJ
Wall Street mixed as Moderna rallies and chips tumble - marketscreener.com
Moderna (MRNA) Shares Surge 15% Following Major Business Update - GuruFocus
Why Moderna Is Today’s Top S&P 500 Stock - Barron's
Moderna stock soars 15% as bulls cheer drug pipeline update: Next stop $75? - MSN
Moderna (NASDAQ:MRNA) Reaches New 12-Month HighHere's Why - MarketBeat
Moderna (MRNA) Sees 14.2% Surge, Reaches $68.23 - GuruFocus
Moderna (NASDAQ:MRNA) gains $3.3 billion after CAR-T update - TechStock²
MRNA Stock Jumps As Flu Win And Pipeline Story Heat Up - StocksToTrade
Moderna jumps 12% after investor day - Breakingthenews.net
Moderna highlights expanding mRNA platform at Science Day - Clinical Trials Arena
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer? - 24/7 Wall St.
MRNA Stock Jumps As Flu Win And Pipeline Reset Ignite Momentum - timothysykes.com
Moderna stock hits 52-week high at $67.78 By Investing.com - Investing.com Canada
Moderna stock hits 52-week high at $67.78 - Investing.com
Moderna (MRNA) Sees 8.7% Gain, Closing at $64.95 - GuruFocus
Piper Sandler raises Moderna stock price target on pipeline progress - Investing.com
Piper Sandler raises Moderna stock price target on pipeline progress By Investing.com - Investing.com Canada
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms - BioSpace
Moderna shows in vivo CAR-T hand in R&D update - pharmaphorum
Jefferies Adjusts Price Target on Moderna to $53 From $45, Maintains Hold Rating - marketscreener.com
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst - The Globe and Mail
FDA Panel Backs Moderna’s mRNA-Based Influenza Vaccine for Adults 50+ - Infectious Disease Advisor
Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh - TradingView
Moderna, Inc. Stock 12‑Month Price Target Raised to $47.45, Implies 21% Downside - TradingView
Moderna Upbeat on New Flu Shot to Help Educate Public About MRNA - Bloomberg
Moderna outlines next phase of mRNA expansion beyond vaccines - The Pharma Letter
Price to book forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
Moderna, Inc. Actuals & Estimates (NASDAQ:MRNA) - TradingView
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Jun 15 '26 |
Option Exercise |
19.15 |
53,336 |
1,021,384 |
1,537,184 |
| Hoge Stephen | President |
Jun 15 '26 |
Sale |
51.37 |
53,336 |
2,739,870 |
1,483,848 |
1.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):